Tag: Cancer therapy
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Janus kinase (JAK) inhibitors provide limited depth and durability of response in myelofibrosis. We evaluated pelabresib—a bromodomain and extrat…
The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer
Most patients with colorectal cancer do not achieve durable clinical benefits from immunotherapy, underscoring the existence of alternative immunos…
Synergistic protection of nascent DNA at stalled forks by MSANTD4 and BRCA1/2–RAD51
The regressed arms of reversed replication forks exhibit structural similarities to one-ended double-stranded breaks and need to be protected again…
Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance
RAF protein kinases are major RAS effectors that function by phosphorylating MEK. Although all three RAF isoforms share a conserved RAS binding dom…
Pharmacodynamics of Akt drugs revealed by a kinase-modulated bioluminescent indicator
Measuring pharmacodynamics (PD)—the biochemical effects of drug dosing—and correlating them with therapeutic efficacy in animal models is cruci…